Consonance-Hfw Acq Corp (SRZN)

$25.22 +0.70 (2.85%)
Market Cap 287.35M
Revenue (ttm) 3.48M
Net Income (ttm) -242.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,954.89%
Debt to Equity Ratio 0.00
Volume 1,003,237
Avg Vol 111,270
Day's Range N/A - N/A
Shares Out 11.61M
Stochastic %K 67%
Beta 0.51
Analysts Strong Sell
Price Target $42.50

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 489 9000
Address:
171 Oyster Point Boulevard, Suite 400, South San Francisco, United States
Jw242
Jw242 Jun. 26 at 8:09 PM
$SRZN 🥱 just a 673k share order at the bell
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 26 at 1:10 PM
$SRZN more from Surrozen today. Daniel Chao had an interview and he published an article together with Diana Do(KOL also connected to Eylea/Regeneron). Hard to ignore for Regeneron. They have to make a move now or risk losing access to WNT drugs. https://www.retinalphysician.com/issues/2026/clinical-trials-at-the-summit/cts-szn8141/
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 26 at 9:30 AM
$SRZN Surrozen hired Kirkland & Ellis for their patent defence against Merck. I was wondering if they have any connection to potential acquirers or if they worked for Regeneron; Roche or BI in the past.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 26 at 7:58 AM
$SRZN so around 250k-500k shares of Surrozen will go into index funds and will be more or less away from the tradable float. For a stock like Surrozen where we already have a very low free float this could be meaningful.
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 25 at 5:48 AM
$SRZN Merck is also trying it in the US this is ongoing since February. https://ai-lab.exparte.com/case/ptab/PGR2026-00027/merck-sharp-dohme-llc-v-surrozen-operating-inc
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 24 at 8:23 PM
$SRZN interesting Merck is starting to attack Surrozen's patents before Brunello trial results. That means Merck is afraid that our patents could block Restoret. That validates Surrozen as the company with the best WNT patent portfolio.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 24 at 1:32 PM
$SRZN some good news for the ophthalmology space today: Ollin raise with support from TCGX https://www.biospace.com/business/ollin-parlays-vabysmo-beat-into-330m-raise-to-test-eye-disease-drug-in-phase-3 Memento starts development of a Tie2 VEGF bispecific and somebody from Sanofi joins their board of directors https://www.ophthalmologytimes.com/view/memento-medicines-launches-with-93-million-series-a-to-advance-tie2-activating-bispecific-for-retinal-disease
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 23 at 7:31 AM
$SRZN this week is Russell 3000 rebalance time so index funds will be forced to buy shares on Friday. Lets see how they will do it.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 17 at 10:16 AM
$SRZN maybe that's why they are hiring because this guy is gone. Seems like 1 year ago they hired for the same part time contract position so maybe they want to fill that one again.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 16 at 6:23 PM
$SRZN followers of Surrozen on Linkedin are increasing fast right now. Not sure if that's because they are hiring or if there's another reason. Normally they are getting maybe 1-2 new followers per day but since yesterday they got around 60 new followers.
0 · Reply
Latest News on SRZN
Surrozen Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 11:30 AM EDT - 5 weeks ago

Surrozen Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Surrozen Transcript: AGM 2026

May 13, 2026, 1:00 PM EDT - 6 weeks ago

Surrozen Transcript: AGM 2026

Surrozen to Present at Upcoming Healthcare Investor Conference

May 12, 2026, 4:05 PM EDT - 6 weeks ago

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen price target raised to $44 from $36 at H.C. Wainwright

2026-05-07T11:30:10.000Z - 7 weeks ago

Surrozen price target raised to $44 from $36 at H.C. Wainwright

Surrozen reports Q1 EPS ($11.65) vs. ($7.43) last year

2026-05-07T01:00:24.000Z - 7 weeks ago

Surrozen reports Q1 EPS ($11.65) vs. ($7.43) last year

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 4:05 PM EDT - 7 weeks ago

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

Surrozen Earnings release: Q1 2026

May 6, 2026, 4:00 PM EDT - 7 weeks ago

Surrozen Earnings release: Q1 2026

Surrozen Quarterly report: Q1 2026

May 6, 2026, 4:00 PM EDT - 7 weeks ago

Surrozen Quarterly report: Q1 2026

Surrozen Slides: Corporate presentation

May 5, 2026, 6:00 PM EDT - 7 weeks ago

Surrozen Slides: Corporate presentation

Surrozen management to meet with Cantor

2026-04-29T22:03:27.000Z - 2 months ago

Surrozen management to meet with Cantor

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 28, 2026, 4:05 PM EDT - 2 months ago

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen initiated with a Buy at TD Cowen

2026-04-21T09:41:40.000Z - 2 months ago

Surrozen initiated with a Buy at TD Cowen

Surrozen Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 3 months ago

Surrozen Proxy statement: Proxy filing

Surrozen Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 3 months ago

Surrozen Proxy statement: Proxy filing

Surrozen price target raised to $36 from $32 at H.C. Wainwright

2026-03-24T10:15:11.000Z - 3 months ago

Surrozen price target raised to $36 from $32 at H.C. Wainwright

Surrozen files $200M mixed securities shelf

2026-03-23T21:30:13.000Z - 3 months ago

Surrozen files $200M mixed securities shelf

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 23, 2026, 4:05 PM EDT - 3 months ago

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen Annual report: Q4 2025

Mar 23, 2026, 4:00 PM EDT - 3 months ago

Surrozen Annual report: Q4 2025

Surrozen Earnings release: Q4 2025

Mar 23, 2026, 4:00 PM EDT - 3 months ago

Surrozen Earnings release: Q4 2025

Surrozen Registration statement: Registration filing

Mar 23, 2026, 8:00 AM EDT - 3 months ago

Surrozen Registration statement: Registration filing

Surrozen Slides: Corporate presentation

Mar 23, 2026, 7:00 AM EDT - 3 months ago

Surrozen Slides: Corporate presentation

Surrozen Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 1:10 PM EST - 4 months ago

Surrozen Transcript: TD Cowen 46th Annual Health Care Conference

Surrozen initiated with an Overweight at Cantor Fitzgerald

2026-02-19T11:15:51.000Z - 4 months ago

Surrozen initiated with an Overweight at Cantor Fitzgerald

Surrozen Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 1:30 PM EST - 4 months ago

Surrozen Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Surrozen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:25 PM EST - 7 months ago

Surrozen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Surrozen Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 9:30 AM EST - 7 months ago

Surrozen Transcript: Piper Sandler 37th Annual Healthcare Conference

Surrozen to Present at Upcoming Healthcare Investor Conferences

Nov 25, 2025, 4:05 PM EST - 7 months ago

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen initiated with an Outperform at LifeSci Capital

2025-11-13T11:15:34.000Z - 8 months ago

Surrozen initiated with an Outperform at LifeSci Capital

Surrozen Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 9:30 AM EST - 8 months ago

Surrozen Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Surrozen names Andrew Maleki as CFO

2025-11-07T21:20:19.000Z - 8 months ago

Surrozen names Andrew Maleki as CFO

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 4:05 PM EST - 8 months ago

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Surrozen Earnings release: Q3 2025

Nov 7, 2025, 4:00 PM EST - 8 months ago

Surrozen Earnings release: Q3 2025

Surrozen Quarterly report: Q3 2025

Nov 7, 2025, 4:00 PM EST - 8 months ago

Surrozen Quarterly report: Q3 2025

Surrozen Slides: Corporate Presentation

Nov 6, 2025, 6:00 PM EST - 8 months ago

Surrozen Slides: Corporate Presentation

Surrozen Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 11:30 AM EDT - 10 months ago

Surrozen Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2025, 4:15 PM EDT - 10 months ago

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Surrozen Transcript: Cantor Global Healthcare Conference 2025

Surrozen Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 7:00 AM EDT - 11 months ago

Surrozen Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 8, 2025, 4:05 PM EDT - 11 months ago

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen Quarterly report: Q2 2025

Aug 8, 2025, 7:00 AM EDT - 11 months ago

Surrozen Quarterly report: Q2 2025

Surrozen Earnings release: Q2 2025

Aug 8, 2025, 7:00 AM EDT - 11 months ago

Surrozen Earnings release: Q2 2025

Surrozen files $150M mixed securities shelf

2025-05-20T20:35:11.000Z - 1 year ago

Surrozen files $150M mixed securities shelf

Surrozen Registration statement: Registration Filing

May 20, 2025, 8:00 AM EDT - 1 year ago

Surrozen Registration statement: Registration Filing

Surrozen granted patent from USPTO directed to antibody-based molecules

2025-05-14T12:37:05.000Z - 1 year ago

Surrozen granted patent from USPTO directed to antibody-based molecules

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025, 8:30 AM EDT - 1 year ago

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025, 4:05 PM EDT - 1 year ago

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Surrozen Earnings release: Q1 2025

May 9, 2025, 12:30 PM EDT - 1 year ago

Surrozen Earnings release: Q1 2025

Surrozen Quarterly report: Q1 2025

May 9, 2025, 12:30 PM EDT - 1 year ago

Surrozen Quarterly report: Q1 2025

Surrozen files to sell 5.21M shares of common stock for holders

2025-04-23T20:29:24.000Z - 1 year ago

Surrozen files to sell 5.21M shares of common stock for holders

Surrozen Registration statement: Registration Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Surrozen Registration statement: Registration Filing

Surrozen Proxy statement: Proxy Filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Surrozen Proxy statement: Proxy Filing

Surrozen Proxy statement: Proxy Filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Surrozen Proxy statement: Proxy Filing

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

2025-03-31T20:40:11.000Z - 1 year ago

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Surrozen Annual report: Q4 2024

Mar 31, 2025, 3:00 PM EDT - 1 year ago

Surrozen Annual report: Q4 2024

Surrozen Earnings release: Q4 2024

Mar 31, 2025, 3:00 PM EDT - 1 year ago

Surrozen Earnings release: Q4 2024

Surrozen to discontinue development of SZN-043 in alcohol associated hepatitis

2025-03-25T19:46:20.000Z - 1 year ago

Surrozen to discontinue development of SZN-043 in alcohol associated hepatitis

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Surrozen initiated with a Buy at H.C. Wainwright

2025-01-30T11:05:29.000Z - 1 year ago

Surrozen initiated with a Buy at H.C. Wainwright

Guggenheim upgrades Surrozen to Buy after ‘encouraging’ SZN-043 data

2025-01-03T12:15:21.000Z - 1 year ago

Guggenheim upgrades Surrozen to Buy after ‘encouraging’ SZN-043 data

Surrozen upgraded to Buy from Neutral at Guggenheim

2025-01-03T11:20:31.000Z - 1 year ago

Surrozen upgraded to Buy from Neutral at Guggenheim

Surrozen Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 2:25 PM EST - 1 year ago

Surrozen Transcript: Stifel 2024 Healthcare Conference

Surrozen Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 3:00 PM EST - 1 year ago

Surrozen Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Nov 6, 2024, 9:00 AM EST - 1 year ago

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen Earnings release: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Surrozen Earnings release: Q3 2024

Surrozen Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Surrozen Quarterly report: Q3 2024

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Nov 4, 2024, 8:30 AM EST - 1 year ago

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Aug 12, 2024, 4:05 PM EDT - 2 years ago

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Surrozen Quarterly report: Q2 2024

Surrozen Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Surrozen Earnings release: Q2 2024

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Jun 12, 2024, 8:30 AM EDT - 2 years ago

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Jun 10, 2024, 8:30 AM EDT - 2 years ago

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 9, 2024, 8:30 AM EDT - 2 years ago

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Provides First Quarter 2024 Financial Results and Business Update

May 8, 2024, 4:05 PM EDT - 2 years ago

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Surrozen Quarterly report: Q1 2024

Surrozen Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Surrozen Earnings release: Q1 2024

Surrozen Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Surrozen Proxy statement: Proxy Filing

Surrozen Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Surrozen Proxy statement: Proxy Filing

Surrozen Registration statement: Registration Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Surrozen Registration statement: Registration Filing

Surrozen Earnings release: Q4 2023

Apr 10, 2024, 4:00 PM EDT - 2 years ago

Surrozen Earnings release: Q4 2023

Surrozen Annual report: Q4 2023

Apr 10, 2024, 4:00 PM EDT - 2 years ago

Surrozen Annual report: Q4 2023

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Apr 3, 2024, 8:40 AM EDT - 2 years ago

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Apr 1, 2024, 8:30 AM EDT - 2 years ago

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Apr 1, 2024, 8:30 AM EDT - 2 years ago

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Surrozen Provides Corporate Update on Clinical Programs

Jan 18, 2024, 8:30 AM EST - 2 years ago

Surrozen Provides Corporate Update on Clinical Programs

Surrozen Provides Third Quarter 2023 Financial Results

Nov 8, 2023, 4:05 PM EST - 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results

Surrozen Quarterly report: Q3 2023

Nov 8, 2023, 7:00 AM EST - 2 years ago

Surrozen Quarterly report: Q3 2023

Surrozen Earnings release: Q3 2023

Nov 8, 2023, 7:00 AM EST - 2 years ago

Surrozen Earnings release: Q3 2023

Surrozen Proxy statement: Proxy Filing

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Surrozen Proxy statement: Proxy Filing

Surrozen Proxy statement: Proxy Filing

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Surrozen Proxy statement: Proxy Filing

Surrozen Proxy statement: Proxy Filing

Oct 13, 2023, 8:00 AM EDT - 2 years ago

Surrozen Proxy statement: Proxy Filing

Surrozen Provides Second Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 3 years ago

Surrozen Provides Second Quarter 2023 Financial Results

Surrozen Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Surrozen Quarterly report: Q2 2023

Surrozen Earnings release: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Surrozen Earnings release: Q2 2023

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Jun 5, 2023, 8:30 AM EDT - 3 years ago

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

May 10, 2023, 4:05 PM EDT - 3 years ago

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Surrozen Quarterly report: Q1 2023

May 10, 2023, 4:00 PM EDT - 3 years ago

Surrozen Quarterly report: Q1 2023

Surrozen Earnings release: Q1 2023

May 10, 2023, 4:00 PM EDT - 3 years ago

Surrozen Earnings release: Q1 2023

Surrozen Proxy statement: Proxy Filing

Apr 6, 2023, 8:00 AM EDT - 3 years ago

Surrozen Proxy statement: Proxy Filing

Surrozen Proxy statement: Proxy Filing

Apr 6, 2023, 8:00 AM EDT - 3 years ago

Surrozen Proxy statement: Proxy Filing

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Apr 5, 2023, 8:30 AM EDT - 3 years ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Surrozen Earnings Call Transcript: Q4 2022

Mar 22, 2023, 4:30 PM EDT - 3 years ago

Surrozen Earnings Call Transcript: Q4 2022

Surrozen Annual report: Q4 2022

Mar 22, 2023, 4:30 PM EDT - 3 years ago

Surrozen Annual report: Q4 2022

Surrozen Earnings release: Q4 2022

Mar 22, 2023, 4:30 PM EDT - 3 years ago

Surrozen Earnings release: Q4 2022

Surrozen Slides: Q4 2022

Mar 22, 2023, 4:30 PM EDT - 3 years ago

Surrozen Slides: Q4 2022

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Mar 22, 2023, 4:01 PM EDT - 3 years ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Mar 20, 2023, 4:30 PM EDT - 3 years ago

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 4, 2023, 4:41 PM EST - 3 years ago

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Surrozen Registration statement: Registration Filing

Dec 9, 2022, 7:00 AM EST - 3 years ago

Surrozen Registration statement: Registration Filing

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:30 PM EST - 3 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Oct 10, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Oct 6, 2022, 8:00 AM EDT - 4 years ago

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Sep 26, 2022, 8:00 AM EDT - 4 years ago

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Surrozen Reports Second Quarter 2022 Financial Results

Aug 11, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Jun 13, 2022, 8:00 AM EDT - 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 24, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 18, 2022, 8:00 AM EDT - 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

May 16, 2022, 8:00 AM EDT - 4 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

Surrozen Reports First Quarter 2022 Financial Results

May 11, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports First Quarter 2022 Financial Results

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 5, 2022, 8:00 AM EDT - 4 years ago

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 2, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Proxy statement: Proxy Filing

Apr 28, 2022, 8:00 AM EDT - 4 years ago

Surrozen Proxy statement: Proxy Filing

Surrozen Proxy statement: Proxy Filing

Apr 28, 2022, 8:00 AM EDT - 4 years ago

Surrozen Proxy statement: Proxy Filing

Surrozen Registration statement: Registration Filing

Mar 29, 2022, 8:00 AM EDT - 4 years ago

Surrozen Registration statement: Registration Filing

Surrozen Annual report: Q4 2021

Mar 28, 2022, 8:00 AM EDT - 4 years ago

Surrozen Annual report: Q4 2021

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 24, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Jan 10, 2022, 8:00 AM EST - 4 years ago

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Jan 5, 2022, 8:00 AM EST - 4 years ago

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 4:00 PM EST - 5 years ago

Surrozen Reports Third Quarter 2021 Financial Results

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Nov 15, 2021, 8:00 AM EST - 5 years ago

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Jw242
Jw242 Jun. 26 at 8:09 PM
$SRZN 🥱 just a 673k share order at the bell
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 26 at 1:10 PM
$SRZN more from Surrozen today. Daniel Chao had an interview and he published an article together with Diana Do(KOL also connected to Eylea/Regeneron). Hard to ignore for Regeneron. They have to make a move now or risk losing access to WNT drugs. https://www.retinalphysician.com/issues/2026/clinical-trials-at-the-summit/cts-szn8141/
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 26 at 9:30 AM
$SRZN Surrozen hired Kirkland & Ellis for their patent defence against Merck. I was wondering if they have any connection to potential acquirers or if they worked for Regeneron; Roche or BI in the past.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 26 at 7:58 AM
$SRZN so around 250k-500k shares of Surrozen will go into index funds and will be more or less away from the tradable float. For a stock like Surrozen where we already have a very low free float this could be meaningful.
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 25 at 5:48 AM
$SRZN Merck is also trying it in the US this is ongoing since February. https://ai-lab.exparte.com/case/ptab/PGR2026-00027/merck-sharp-dohme-llc-v-surrozen-operating-inc
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 24 at 8:23 PM
$SRZN interesting Merck is starting to attack Surrozen's patents before Brunello trial results. That means Merck is afraid that our patents could block Restoret. That validates Surrozen as the company with the best WNT patent portfolio.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 24 at 1:32 PM
$SRZN some good news for the ophthalmology space today: Ollin raise with support from TCGX https://www.biospace.com/business/ollin-parlays-vabysmo-beat-into-330m-raise-to-test-eye-disease-drug-in-phase-3 Memento starts development of a Tie2 VEGF bispecific and somebody from Sanofi joins their board of directors https://www.ophthalmologytimes.com/view/memento-medicines-launches-with-93-million-series-a-to-advance-tie2-activating-bispecific-for-retinal-disease
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 23 at 7:31 AM
$SRZN this week is Russell 3000 rebalance time so index funds will be forced to buy shares on Friday. Lets see how they will do it.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 17 at 10:16 AM
$SRZN maybe that's why they are hiring because this guy is gone. Seems like 1 year ago they hired for the same part time contract position so maybe they want to fill that one again.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 16 at 6:23 PM
$SRZN followers of Surrozen on Linkedin are increasing fast right now. Not sure if that's because they are hiring or if there's another reason. Normally they are getting maybe 1-2 new followers per day but since yesterday they got around 60 new followers.
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 15 at 7:56 AM
$SRZN from the CTS Retina event. Not sure if that data is old or new but they are pushing harder and harder and are getting more interest from other people/companies.
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 13 at 6:53 AM
$SRZN interesting Surrozen is hiring again but only part time contract positions for some months. That supports the idea that they don't want to grow the company and only need some support until a buyout is finished. Even though they lost multiple employees recently they never rehired somebody for those positions. And they don't hire any people for opthalmology clinical or regulatory functions. They work with what they have. They outsource a lot and keep the company lean and new hires are only part time contractors. A company that knows it has to build an organisation for years of clinical development wouldn't act like that.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 11 at 1:12 PM
$SRZN Surrozen will present at this conference on the weekend.
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 9 at 8:06 AM
$SRZN TCGX bought heavily around $20-24 so this should be their buying zone now. If they don't buy more and also don't buy more if it goes lower then it probably means they are not allowed to buy shares right now. We all know what that could mean. Also Point72 was buying over $30 even though they know about the second tranche shares at $11.6. So that's also a good signal.
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 8 at 6:48 PM
$SRZN weakness could be related to the index inclusion. Push down the share price so the forced index inclusion buying will not push the share price to new highs. Index funds want to buy as cheap as possible so the fact that Surrozen is on the Russell 3000 list makes us a target for them.
0 · Reply
Scorpole
Scorpole Jun. 8 at 3:42 PM
$SRZN It seems, that shorters know, that warrants will be exercised at 13,20.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 8 at 1:47 PM
$SRZN limbal stem cell deficiency is another condition that we could probably treat with a WNT drug. It seems like FZD7 could be one of the main targets. That is an orphan disease so whoever develops a drug there gets orphan designation. https://iovs.arvojournals.org/article.aspx?articleid=2791040
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 8 at 1:25 PM
$SRZN a new publication from other scientists regarding "The role of Wnt signalling in the pathogenesis and therapy of age-related macular degeneration (AMD)". They also mention our drugs so see it as a little peer review which is always good. https://www.sciencedirect.com/science/article/pii/S0006295226004491
0 · Reply
BuyoutBobby
BuyoutBobby Jun. 7 at 8:15 AM
$SRZN looks like there's another reason why Boehringer Ingelheim wants to invest more money into the US. A buyout of Surrozen could help them to reach the $10 billion in US investments. Their best/only chance to win a bidding war is before Brunello trial results are known which is around September. https://www.prnewswire.com/news-releases/boehringer-ingelheim-announces-broad-agreement-with-the-us-government-to-lower-the-cost-of-medicines-for-american-patients-and-expand-its-us-footprint-302647232.html?utm_source=chatgpt.com
0 · Reply
Scorpole
Scorpole Jun. 2 at 4:16 PM
$SRZN The deroute of SP is complete. Lost 33% in 3 weeks without any info. It started right after the ER for Q1. Have we missed something? Or fair price is below $20.
1 · Reply
BuyoutBobby
BuyoutBobby May. 30 at 7:35 PM
$SRZN some index funds will have to buy shares of Surrozen because we will be added to the Russell 3000 index in June.
1 · Reply
Scorpole
Scorpole May. 29 at 2:39 PM
$SRZN Short interest has rose to 546224 shares from around 425000 this month. I don’t get it, since stutes own most of the company. It will be hard for shorters to buy back if stutes keep their shares.
1 · Reply